CENPA has long been considered to be up-regulated in a variety of malignant tumors, especially prostate cancer, and can promote tumor growth, drug resistance, and metastasis.[19,20] In our risk model, RBM14 is the only highly expressed gene in the low-risk group. This evidence concerns the gene CENPA and prostate carcinoma.